Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
Tiziana Vavalà, Silvia Novello, Tiziana Vavalà, Silvia Novello
Abstract
Anaplastic lymphoma kinase (ALK) rearrangement is identified in 3-7% of advanced non-small cell lung cancer (NSCLC) cases, and ALK tyrosine kinase inhibitors (TKIs) have revolutionized the management of this subset of NSCLC patients. ALK-TKIs have been proven highly effective in ALK-rearranged advanced NSCLC patients, but after initial responses and benefit, a subsequent progression inevitably occurs. Understanding acquired-resistance mechanisms and defining an appropriate algorithm is becoming even more essential, particularly considering the availability of extremely efficacious next-generation ALK inhibitors. The aim of this review is the analysis of current data about ALK inhibition as a therapeutic strategy in ALK-rearranged NSCLC management, with a focus on a specific ALK-TKI, alectinib. Alectinib is a highly selective inhibitor of ALK and showed systemic and central nervous system (CNS) efficacy in the treatment of this particular population. The change of first-line approach, and consequently of further lines of therapy, in ALK-rearranged NSCLC patients is still a matter of debate. A summary of evidence from randomized trials evaluating alectinib will be presented in order to discuss the available clinical evidence, safety and place in therapy.
Keywords: ALK; ALK inhibitors; ALK-rearranged NSCLC; ALK–TKI; ALK–tyrosine kinase inhibitors; EML4–ALK; NSCLC; alectinib; alectinib clinical trials; non-small cell lung cancer.
Conflict of interest statement
Conflict of interest statement: Dr Tiziana Vavalà declares no conflicts of interests. Professor Silvia Novello declares these conflicts of interests in the last 3 years: speaker bureau Eli Lilly, BMS, BI, Incyte, MSD, Roche and Astra Zeneca.
References
- WHO Statistics. (accessed 21 December 2017).
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
- Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009; 4: 1450–1454.
- Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13: 685–700.
- Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994; 263: 1281–1284.
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561–566.
- Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190–1203.
- Kris M, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998–2006.
- Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247–4253.
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693–1703.
- Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46: 1773–1780.
- Sabir SR, Yeoh S, Jackson G, et al. EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers 2017; 9: 1–9.
- Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK positive lung cancer. Clin Cancer Res 2009; 15: 3143–3149.
- Hernandez L, Pinyol M, Hernandez S, et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999; 94: 3265–3268.
- Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012; 7: e31323.
- Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 2018; 13: 323–358.
- Casaluce F, Sgambato A, Sacco PC, et al. Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies. Curr Clin Pharmacol 2016; 11: 77–87.
- Galetta D, Rossi A, Pisconti S, et al. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets 2012; 16(Suppl. 2): SS45–SS54.
- Rossi A. Alectinib for ALK-positive non-small-cell lung cancer. Exp Rev Clin Pharmacol 2016; 9: 1005–1013.
- Hofman P. ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers 2017; 9: 1–16.
- Mezquita L, Besse B. Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. J Thorac Dis 2016; 8: 2997–3002.
- XALKORI [Package Insert]. New York, NY: Pfizer, Inc, 2011.
- Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167–2177.
- Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389: 917–929.
- Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015; 33: 1881–1888.
- Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 2017; 7: 137–155.
- Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013; 368: 2395–2401.
- Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non small cell lung cancer. Clin Cancer Res 2012; 18: 1472–1482.
- Boland JM, Jang JS, Li J, et al. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol 2013; 8: 574–581.
- U.S. Food and Drug Administration. FDA D.I.S.C.O.: two approvals for ALK-positive non-small cell lung cancer, (accessed 25 January 2018).
- Uemura T, Hida T. Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer. Ann Transl Med 2017; 5: 433.
- Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer. Cancer Discov 2016; 6: 1118–1133.
- Muller IB, de Langen AJ, Giovannetti E, et al. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther 2017; 10: 4535–4541.
- Hamilton G, Rath B, Burghuber O. Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol 2015; 11: 835–842.
- Muller IB, De Langen AJ, Honeywell RJ, et al. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Rev Anticancer Ther 2016; 16: 147–157.
- ALECENSA: alectinib hydrochloride capsule, (accessed 25 January 2018).
- Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014; 15: 1119–1128.
- Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014; 74: 1023–1028.
- Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29: e443–e445.
- Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013; 14: 590–598.
- Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17: 234–242.
- Camidge DR, Gadgeel S, Ou SH, et al. MA07.02 updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer. J Thoracic Oncol 2017; 12(Suppl.): S378.
- Ou SHI, Ahn JS, De Petris L. Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol 2016; 34: 661–668.
- Barlesi F, Dingemans AMC, Ou I, et al. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer 2015; 51(Suppl. 3): S635.
- Novello S, Mazieres J, Oh I-J, et al. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol 2017; 28(Suppl. 5): v605-v649.
- Kim Y, Hida T, Nokihara H, et al. Alectinib (ALC) versus Crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from phase III study (J-ALEX). J Thoracic Oncol 2017; 12(Suppl.): S378.
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377: 829–838.
- Tamura T, Kiura K, Seto T, et al. Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol 2017; 35: 1515–1521.
- Ou SHI, Gandhi L, Gadgeel SM, et al. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2018; 36(Suppl.): abstract 9072.
- Morcos PN, Nueesch E, Jaminion F, et al. Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. Epub ahead of print 10 May 2018. DOI: 10.1007/s00280-018-3597-5.
- Mok TSK, Peters S, Camidge DR, et al. Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Ann Oncol 2017; 28(Suppl. 10): x186–x195.
- Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390(10089): 29–39.
- Zhu V, Ou SH. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf 2017; 16: 509–514.
- Gadgeel SM, Shaw AT, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol 2016; 34: 4079–4085.
- Ou SHI, Sommers KR, Azada MC, et al. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 2015; 20: 224–226.
- Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015; 10: 232–236.
- Tran PN, Klempner SJ. Focus on alectinib and competitor compounds for second-line therapy in ALK-rearranged NSCLC. Front Med (Lausanne) 2016; 3: 65.
- Gadgeel SM, Shaw AT, Barlesi F, et al. Cumulative incidence rates for CNS andnon-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC Br J Cancer 2018; 118: 38–42.
- Gainor JF, Chi AS, Logan J, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol 2016; 11: 256–260.
- Yoshida T, Oya Y, Tanaka K, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer. J Clin Oncol 2016; 34: 3383–3389.
- Woo CG, Seo S, Kim SW, et al. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol 2017; 28: 791–797.
- Uemura T, Hida T. Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer. Ann Transl Med 2017; 5: 433: 1–6.
Source: PubMed